ITV-1 aka "SNAKE OIL BULLSHIT"
Patent US-7479538
Enzolytics has a License Agreement for US Patent 7479538. The claim is Irreversibly-inactivated Pepsinogen Fragments for Modulating Immune Function.
Enzolytics, Inc.'s flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.
This bio-product has shown low toxicity and is well accepted by the body system. Clinical trials in Bulgaria show improvements in immunity.
ITV-1 has been through Phase I, II and III clinical Trials however due to ENZC being informed that the inclusion of the BDA in the EMA restricted the permitting of our Treatment by the BDA and the permitting will now be done by the EMA for all the European Union. As a result, some, if not all of the Phase III clinical trials may need to be completed under the EMA standards.Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.
Cell line is a general term that applies to a defined population of cells that can be maintained in culture for an extended period of time, retaining stability of certain phenotypes and functions. Cell lines are usually clonal, meaning that the entire population originated from a single common ancestor cell.
Clone 3
The Company has clarified the lack of significance of the prior expired Company patents covering the Company's "parent" Clone 3 anti-HIV antibody. The expired Company patents were issued on the "parent" Clone 3 antibody. As is the case with virtually all parent antibodies, the parent antibody is a "slow producer" - which means it could not produce sufficient antibody therapeutics to treat the 36 million individuals infected with HIV. Thus, a recombinant form of the antibody had to be created employing a fast-producing CHO cell line. This has been accomplished by the Company and patent applications are pending claiming the recombinant form of the antibody, the form that will be used in patient therapy. The term of issued patents will be 20 years from filings, such filings having been made in 2020.
AI
